TP53 and neoplasm: To further investigate whether the putative gain-of-function TP53 mutations may affect tumor growth differently compared to loss-of-expression TP53 mutations, we used CRISPR-Cas9 gene editing to functionally inactivate the Trp53GoF allele in Trp53GoF/− organoids to yield a co-isogenic Trp53CRISPR-KO/− (KO, knockout) organoid clone (Figure S3D).